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Despite many years of research, a dengue vaccine is not available, and the more advanced live attenuated vaccine candidate in
clinical trials requires multiple immunizations with long interdose periods and provides low protective efficacy. Here, we report
important contributions to the development of a second-generation dengue vaccine. First, we demonstrate that a nonpropagat-
ing vaccine vector based on Venezuelan equine encephalitis virus replicon particles (VRP) expressing two configurations of den-
gue virus E antigen (subviral particles [prME] and soluble E dimers [E85]) successfully immunized and protected macaques
against dengue virus, while antivector antibodies did not interfere with a booster immunization. Second, compared to prME-
VRP, E85-VRP induced neutralizing antibodies faster, to higher titers, and with improved protective efficacy. Third, this study is
the first to map antigenic domains and specificities targeted by vaccination versus natural infection, revealing that, unlike prME-
VRP and live virus, E85-VRP induced only serotype-specific antibodies, which predominantly targeted EDIII, suggesting a pro-
tective mechanism different from that induced by live virus and possibly live attenuated vaccines. Fourth, a tetravalent E85-VRP
dengue vaccine induced a simultaneous and protective response to all 4 serotypes after 2 doses given 6 weeks apart. Balanced
responses and protection in macaques provided further support for exploring the immunogenicity and safety of this vaccine can-
didate in humans.
Dengue fever (DF) is a viral disease characterized by severeheadache, skin rash, and debilitating muscle and joint pain.
Severe cases are associated with circulatory failure, shock, coma,
and death. The disease is caused by any of 4 dengue virus sero-
types, 1, 2, 3, and 4 (DENV1 to -4), members of the family Flavi-
viridae, which are transmitted among humans by the mosquito
Aedes aegypti. DENVs are considered the most important emerg-
ing human arboviruses, with worldwide distribution in the trop-
ics, and are responsible for an estimated 36 million cases of DF,
more than 2 million cases of severe dengue hemorrhagic fever and
dengue shock syndrome (DHF/DSS), and more than 21,000
deaths every year (1–4). Currently, there are no licensed dengue
vaccines available.
The development of a dengue vaccine faces unique challenges.
The 4 serotypes cocirculate in areas of endemicity, and preexisting
immunity to one serotype confers only short-term protection
against infection with other serotypes. In addition, epidemiolog-
ical studies suggest that preexisting cross-reactive antibodies
and/or T cells elicited by one serotype may enhance the severity of
disease upon infection with a heterologous serotype (reviewed in
reference 5). This is partly attributed to the phenomenon of anti-
body (Ab)-dependent enhancement (ADE), by which preexisting
cross-reactive, nonneutralizing antibodies can enhance infection
and the disease severity of a subsequent infection (6–8). There-
fore, for a dengue vaccine to be safe and effective, it has to induce
long-lasting protective immunity to all 4 serotypes simultaneously
and must do so soon after immunization to avoid sensitizing the
vaccine recipient to enhanced disease. While it is clear that both
antibody and T cell immunities play a role in protection from
disease and viral clearance, it is not fully understood what qualities
of the immune response, in terms of potency, breadth, and anti-
gen/epitope specificities, are required for a vaccine to be protective
in humans.
Most dengue vaccine research efforts for the past 2 decades
have been to develop live attenuated virus (LAV) vaccine plat-
forms. A major challenge of this platform has been achieving suf-
ficient attenuation for each monovalent component while pre-
serving immunogenicity for all 4 serotypes. There are three LAV
vaccine candidates under active clinical development (9–11).
These vaccines are based on recombinant attenuated and chimeric
viruses representing each of the four dengue serotypes. In the chi-
meric yellow fever-dengue tetravalent vaccine, ChimeriVax/CYD-
TV, used by Acambis/Sanofi Pasteur, each component contains
the genome of the yellow fever vaccine strain 17D, in which the
premembrane (prM) and envelope (E) genes of each dengue virus
serotype have been substituted for the analogous yellow fever
genes (12–14). In the case of the tetravalent vaccine (TetraVax-
DV) developed by the Laboratory of Infectious Diseases at the
National Institute of Allergy and Infectious Diseases (NIAID),
each component has been attenuated either by defined attenuat-
ing deletion mutations in the 3= untranslated region (UTR) or by
chimerization (15, 16). In the case of the chimeric DENVax devel-
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oped by the U.S. CDC and Inviragen, each component is a chime-
ric virus containing the prM and E genes of DENV1, -3, and -4 in
the genome background of the attenuated vaccine strain DENV2
PDK-53 developed by Mahidol University, Bangkok, Thailand
(reviewed in reference 11). These three LAV vaccine candidates
are in different stages of clinical phase 1 and 2 trials and have
shown short-term safety and immunogenicity (17, 18; J. E. Oso-
rio, Presented at the Third Panamerican Dengue Research Net-
work Meeting, Cartagena, Colombia, 2012). The first efficacy data
for a LAV were recently reported from a phase 2b study conducted
in Thailand with Sanofi Pasteur’s CYD tetravalent vaccine (19).
Although the geometric mean neutralizing-Ab levels against the 4
serotypes were higher in vaccinees than in controls, only modest
levels of overall protection (30%) and no protection against
DENV2 were observed in the study (19). Although ongoing phase
3 trials may reveal improved efficacy with a larger number of study
subjects, these early clinical trial results underscore the need to
better understand qualitative and quantitative requirements for a
vaccine-induced protective immune response.
Another major challenge faced by LAV vaccine platforms is
interference among the four serotype components in the vaccine,
causing some serotypes to be dominant over or to interfere with
other serotypes in the tetravalent mixture. This has been more
evident in the case of the Sanofi Pasteur vaccine and with older
LAV attempts no longer in active development (20, 21). This
problem was overcome with a three-dose LAV vaccine schedule,
administered over a 1-year period in the case of the Sanofi Pasteur
vaccine. However, such a long immunization schedule would be
difficult to complete in resource-poor countries. Under this sce-
nario, vaccinees would be at increased risk during the 12-month
vaccination period, and this increased risk would be long term if
an individual received only one or two of the required vaccine
doses. While these theoretical concerns are being addressed in
clinical trials, there is an urgent need to accelerate the develop-
ment of second-generation dengue vaccines into clinical trials,
with emphasis on overcoming viral interference among the tet-
ravalent vaccine components and utilizing shorter dosing inter-
vals. A number of nonpropagating vaccine strategies are in devel-
opment. They include (i) adjuvanted recombinant E protein
expressed in Drosophila S2 cells (reviewed in reference 22), cur-
rently in phase 1 clinical testing; (ii) plasmid DNA expressing prM
and E proteins, currently in phase 1 clinical testing (23); (iii) ad-
juvanted inactivated virus (24); (iv) modified adenovirus and al-
phavirus as viral vectors expressing DENV envelope protein se-
quences (25–28); and (v) recombinant E domain III (29–32;
reviewed in references 33 and 34).
The envelope of DENV contains two transmembrane glyco-
proteins, envelope (E) and premembrane/membrane (prM/M).
E, which is involved in viral binding and entry into cells, is the
most important target of neutralizing antibodies (35). The E pro-
tein is about 500 amino acids long. The ectodomain (N-terminal
400 residues) has been crystallized, and the atomic structure
shows 3 -barrel domains, represented as EDI, EDII, and EDIII
(36). Mouse monoclonal antibodies (MAbs) that neutralize
DENV map to all three domains (35). However, the monoclonal
antibodies with the strongest neutralization are serotype specific
and map to EDIII (37–42), which is a region of 100 amino acids
that folds into an immunoglobulin-like domain and has been im-
plicated in host receptor binding (43). The minor surface glyco-
protein, prM/M, plays a role in proper folding of E and particle
assembly and is present as uncleaved prM in the immature particle
and partly or fully cleaved M in the mature particle (44).
The antigenic composition and the relative contributions of
neutralizing and potentially enhancing epitopes are important
considerations in the design of a safe and effective dengue vaccine.
However, important knowledge gaps still exist. It is unclear
whether mimicking the human immune response to natural in-
fection would be the best vaccination strategy, and the main
epitopes on DENV targeted by strongly neutralizing antibodies in
the human immune sera remain to be defined. Recent studies have
begun to define the specificity of the human antibody response to
dengue virus by studying human immune sera and human mono-
clonal antibodies (reviewed in reference 45). A major population
of highly cross-reactive, weakly neutralizing, and infection-en-
hancing specific antibodies that bind to prM are elicited in re-
sponse to natural dengue infection (46). The fusion loop in EDII is
also a major target of antibodies present in human immune sera
(47). Human MAbs with neutralizing activity bind to (i) complex
epitopes preserved on the intact virion but not on recombinant E
protein (48), (ii) E domains I/II, and (iii) epitopes on the lateral
ridge and A strand of EDIII (49). It is important to note that
human MAbs with infection-enhancing activity have mapped to
prM, EDI/II, and EDIII (50).
Alphavirus-derived replicon vectors have been developed as a
vaccine platform (51). Venezuelan equine encephalitis virus
(VEE) replicon particles (VRP) are defective, nonpropagating vi-
rus-like particles that contain a modified genome expressing high
levels of a vaccine antigen. VRP target dendritic cells in the drain-
ing lymph nodes of immunized animals (52), where amplification
of the replicon RNA results in strong induction of innate immu-
nity and the vaccine antigen is expressed in immunogenic
amounts (53, 54). Alphavirus replicon particle vaccines have been
studied extensively in recent years and have conferred protective
immunity to a wide variety of viral and bacterial antigens tested in
different animal models with an exceptional safety record (55–
60). More importantly, the layered safety features of the VRP sys-
tem have been assessed in humans in phase I clinical trials of VRP
expressing the Gag protein of clade C HIV (61) and cytomegalo-
virus gB or a pp65/IE1 fusion protein (62).
The feasibility of the VRP platform as a dengue vaccine was
demonstrated previously in mice. Two doses of DENV2 prME-
VRP were immunogenic and protective in BALB/c mice (28) and,
when formulated as a tetravalent VRP cocktail, induced balanced
responses that lasted at least 71 weeks after the second dose (L. J.
White, unpublished data). Also, Chen et al. reported that heterol-
ogous prime/boost immunizations with DENV1 prME DNA
prime/VRP boost were immunogenic and protective in nonhu-
man primates (NHPs) (63).
The goals of this study were (i) to determine how the magni-
tude and quality of the antibody responses induced by different
vaccine antigen configurations compare to antibody responses in-
duced after dengue virus infection and (ii) to determine whether
the VRP vaccine overcomes some of the challenges faced by first-
generation LAV dengue vaccines. We first compared in macaques
the antibody responses induced by vaccination with monovalent
VRP expressing two configurations of E protein, prME and E85,
with those induced by infection with live virus. We then con-
structed and evaluated a tetravalent VRP vaccine expressing the
antigen that best performed in the monovalent test, E85. This
tetravalent formulation provided 100% seroconversion against all
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4 serotypes after only 2 vaccine doses given 6 weeks apart, with no
evidence of interference among the components of the vaccine.
Protection against virus challenge from each serotype was dem-
onstrated, and antivector immunity against the first dose did not
seem to reduce the effectiveness of a second dose. These results
suggest that the tetravalent VRP dengue vaccine should receive
serious consideration as a next-generation dengue vaccine candi-
date.
MATERIALS AND METHODS
Cells. BHK-21 and Vero-81 cells were obtained from the American Type
Culture Collection (ATCC). The BHK-21 cells were maintained in alpha
minimal essential medium (alpha-MEM) containing 10% donor calf se-
rum, 10% tryptose phosphate broth, penicillin (100 U/ml), and strepto-
mycin (100 g/ml) in the presence of 5% CO2. Vero-81 cells were main-
tained at 37°C in Dulbecco’s modified Eagle’s medium (DMEM)/F12
medium supplemented with 10% fetal calf serum, penicillin (100 U/ml),
and streptomycin (100 g/ml) in the presence of 5% CO2. Insect C6/36
cells were obtained from the ATCC and maintained at 28°C in alpha
minimal essential medium containing 5% fetal calf serum, penicillin (100
U/ml), and streptomycin (100 g/ml) in the presence of 5% CO2.
Viruses. Contemporary clinical DENV isolates with low cell culture
passage histories were used as the sources of dengue virus genes to be
expressed by the VRP vaccine vectors. The sequences are identified by
their University of North Carolina (UNC) nomenclature and place and
year of isolation: serotype 1, strain UNC 1017, Sri Lanka, 2004; serotype 2,
strain UNC 2055, Brazil, 2008; serotype 3, strain UNC 3001 (genotype
III), Sri Lanka, 1989; serotype 4, strain UNC 4019, Colombia, 2006.
DENV strains used for monkey challenge studies were obtained from
Steve Whitehead (NIAID). DENV1 WP, Western Pacific, 1974 (accession
number AY145121); DENV2 NGC, New Guinea, 1944 (accession number
AY243467); DENV3 Sleman/78, Indonesia, 1978 (accession number
AY648961); and DENV4-814669, Dominica, 1981 (accession num-
ber AF326573) have been used in previous dengue virus challenge studies
in monkeys due to their ability to replicate and cause detectable viremia in
macaques (64). They were passaged once in Vero cells in our laboratory
and stored at 80°C. The viruses used in neutralization assays have been
assigned by the World Health Organization as dengue virus reference
strains and were provided by R. Putnak from WRAIR (DENV1 WP,
DENV2 S-16803, DENV3 CH53489 [genotype II], and DENV4 TVP-
360). In addition, we used strains from DENV3 genotype I (UNC 3043,
strain 059.AP-2 from the Philippines, 1984), and DENV3 genotype IV
(UNC 3036, strain 1342 from Puerto Rico, 1977). These viruses were
propagated two or three times in C6/36 cells, titrated on Vero cells, and
stored at 80°C. The virus preparations used as antigens to coat enzyme-
linked immunosorbent assay (ELISA) plates were obtained by further
purification and concentration of the C6/36-grown virus stock, as de-
scribed previously (65).
Cloning of DENV prME and E85 into VEE vectors. DENV genes were
cloned into the VEE replicon plasmid, pVKE (pVR21 with KanR and
EcoRV) (28), as follows. Viral RNA was extracted from virus growth cul-
ture media and used as the template to generate cDNA by reverse tran-
scription-PCR. The forward PCR primer was designed to insert an EcoRV
restriction site at the 5= end, where the last 3= G constitutes the first nu-
cleotide of the first methionine codon, followed by the second and third
nucleotides of the Met start codon (AT). The reverse primer was designed
to add a stop codon followed by an AscI or PacI site at the 3= end. The
sequences of the primers used to amplify the different constructs are as
follows: for DENV1 prME, forward, 5=-GGGGTTTAAAAAAGAGATCT
CAAGC-3=, and reverse, 5=-GCCATTAATTAACTACGCTTGAACCAT
GACTCC-3=; for DENV1 E85, forward, 5=-GTCCATCACCCAGAAAGG
GATC-3=, and reverse, 5=-GCCATTAATTAACTAGGAACCGAAGTCC
CATG-3=; for DENV2 prME, forward, 5=-GGGGTTCAGGAAAGAGAT
TG-3=, and reverse, 5=-GCTTTTAATTAACTAAGCCTGCACCATAGCT
C-3=; for DENV2 E85, forward, 5=-GACACACTTCCAAAGGGCCTTG-
3=, and reverse, 5=-GCTATTAATTAACTAGGATCCAAAATCCCAGG
C-3=; for DENV3 prME, forward, 5=-GGGCTTCAAGAAGGAGATCTC
AAACATGCTGAGCATAATCAAC-3=, and reverse, 5=-GGTGCAGGCG
CGCCCTAAGCTTGTACCACAGCTCCCAGATAGAGTGTAAT-3=; for
DENV3 E85, forward, 5=-GTCCTTGACCCAGAAGGTGGTTATTTTTA
TACTACTAATGCTGGTCACCCCATCCATGACAATGAGATGTGTG
GGAATAGGA-3=, and reverse, 5=-GGTGCAGGCGCGCCCTATGATCC
AAAGTCCCAAGCTGTGTCTCCCAAGAT-3=; for DENV4 prME,
forward, 5=-GGGATTCAGGAAGGAGATAGGC-3=, and reverse, 5=-GC
TATTAATTAACTACGCTTGAACCGTGAAGCC-3=); for DENV4 E85,
forward, 5=-GACAGGAATCCAGCGAACAGTC-3=, and reverse 5=-GCC
ATTAATTAACTAGGAACCAAAATC-3=. The prME cassette contained
sequences encoding the last 18 residues from the capsid protein serving as
a signal peptide for prM, followed by full-length prM and full-length E.
The E85 construct contained a C-terminally truncated soluble form of E
that represents 85% of the protein, including sequences encoding the E
signal peptide (the last 18 residues from prM); domains I, II, and III of the
ectodomain; the first alpha helix, H1, and part of the conserved sequence,
CS (E residues 1 to 424 for DENV1, -2, and -4 and residues 1 to 422 for
DENV3), and lacking the second alpha helix, H2, and the 2 transmem-
brane domains. The amplified regions were digested with AscI or PacI and
cloned into the VEE replicon vector pVKE digested with EcoRV and AscI
or PacI.
Assembly and purification of VRP. Production of VRP expressing
dengue virus antigens was done as described previously (28). Briefly, the
clones were linearized at a unique NotI site downstream of the VEE 3=
untranslated region and poly(A) tract, and full-length T7 transcripts were
generated in vitro using an mMessage mMachine kit (Ambion) as previ-
ously described. To package the recombinant replicon genome into VRP
for delivery in vitro and in vivo, the replicon RNA was mixed with two
helper RNAs encoding the capsid gene and the attenuated glycoprotein
from V3014, also transcribed in vitro using T7 polymerase, as previously
described (28). The transcripts were cotransfected into BHK cells by elec-
troporation. The culture medium was harvested at 22 to 24 h postelectro-
poration and clarified, and the VRP were partially purified and concen-
trated by ultracentrifugation. Each VRP preparation was safety tested as
described previously to ensure the absence of propagation-competent vi-
rus that could have arisen by nonhomologous recombination during
packaging (28). VRP titers were determined in BHK cells by indirect im-
munofluorescence assay (IFA), using mouse polyclonal antibody against
VEE nonstructural proteins, and expressed as IU/ml (28).
In vitro expression of DENV E protein in VRP-infected BHK cells.
Subconfluent BHK-21 cells grown in 24-well plates were mock infected or
infected at an MOI of 10 with VRP expressing DENV3 prME or E85 in
duplicate. At 19 h postinfection, culture medium (0.5 ml) was collected
and clarified by centrifugation. The cells were washed with cold phos-
phate-buffered saline (PBS) and lysed with 100 l of NP-40 lysis buffer in
the presence of protease inhibitors. Samples were analyzed for the pres-
ence of E protein by nonreducing SDS-PAGE, followed by Western blot-
ting. Each lane was loaded with 35 l of cell lysate (out of 100 l/infected
well) or 35 l of clarified culture medium (out of 0.5 ml/infected well).
The electrophoresed proteins were transferred onto polyvinylidene diflu-
oride (PVDF) membranes and probed with mouse MAb 4G2, which
binds to EDII of the flavivirus E protein. Following incubation with goat
anti-mouse IgG-horseradish peroxidase (HRP), the membranes were de-
veloped using enhanced chemiluminescence (ECL) substrate.
ELISA with EDII dimer interface antibodies. Two antibodies that
bind to the interfaces of adjacent E protein dimers, kindly provided by M.
Diamond, Washington University (40), were used to determine whether
E85 protein expressed from the VRP vector forms E dimers. ELISA plates
were coated with mouse monoclonal antibodies DV2-46 and DV2-58
overnight at 4°C. The plates were washed with Tris-buffered saline with
0.2% Tween 20 (TBST wash buffer) and blocked with 5% skim milk in
Tris-buffered saline with 0.05% Tween 20 (TBST blocking buffer) for 1 h
at 37°C. Serially diluted supernatant and cell lysate from DENV2 E85-
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VRP-infected Vero cells in TBST blocking buffer were then added to each
well and incubated for 1 h at 37°C. After washing 3 times with TBST wash
buffer, the plates were incubated for 1 h at 37°C with 100 ng of EDIII-
reactive human MAb 1M23 (50). The plates were washed and incubated
with alkaline phosphatase-conjugated goat anti-human antibody (Sigma)
and then washed 3 times with TBST wash buffer and developed by adding
p-nitrophenyl phosphate substrate (Sigma). The optical density (OD) was
measured at 405 nm using a spectrophotometer. Serially diluted recom-
binant E80 protein purchased from Hawaii Biotech was used as a positive
control.
DENV neutralization assays. DENV serotype-specific neutralizing
antibodies in immunized macaque sera were quantified using a flow cy-
tometry-based neutralization assay on Vero cells, as described previously
(28, 66, 67). The assay has been previously validated by head-to-head
comparison with a classical plaque reduction neutralization assay (PRNT)
in a study using a panel of WHO reference sera from all 4 serotypes and
convalescent-phase sera from patients (66). It has the advantage of re-
duced performance time from 1 week to 3 days, a higher-throughput
format, and the ability to measure the neutralization of clinical isolates
and viral strains that have not been adapted to grow on Vero or BHK cells
and that do not plaque well in the PRNT. In the flow-based assay, the
ability of immune serum to neutralize the infectivity of DENV on Vero
cells is measured at 24 h postinfection (p.i.) by enumerating cells that are
positive for intracellular staining of DENV prM or E protein by flow
cytometry. The strains of DENV used in this assay were reference strains
provided by WHO representing each serotype, as specified above. Where
indicated, strains representing genotypes I through IV within serotype 3
were used. The controls included in each assay were (i) mock-infected
cells, (ii) cells infected with DENV in the absence of immune sera or with
preimmune sera, and (iii) cells infected with DENV preincubated with a
reference DENV immune serum. The percent neutralization for each di-
lution was defined as the reduction in the number of E-antigen-positive
cells in the test sera compared with the number of positive cells in the
virus-only control. The neutralization titer (Neut50 titer) for each serum
sample was expressed as the reciprocal of the titer that reduced infection
to 50% (50% effective concentration [EC50]), calculated using nonlin-
ear regression analysis, sigmoidal model.
VEE neutralization assay. VEE-specific neutralization titers in sera
from VRP-immunized animals were determined using a flow cytometry-
based neutralization assay. Briefly, BHK cell monolayers were seeded in
24-well plates at a density of 105 cells per well. Control or immune sera
were diluted 2-fold with alpha-MEM containing 1% bovine serum albu-
min, and each dilution was mixed with an equivalent volume of a VRP
expressing green fluorescent protein (GFP-VRP) to give a multiplicity of
infection (MOI) of 0.1 in a total volume of 110 l. The mixture was
incubated for 1 h at 37°C in 5% CO2 before transferring it to BHK cell
monolayers in 24-well plates. Each serum dilution was tested in duplicate
wells. After 1 h of adsorption, complete medium was added, and the plates
were incubated for 24 h at 37°C. To enumerate infected cells, the mono-
layers were washed with PBS, trypsin treated, washed again with PBS, and
fixed in 2% paraformaldehyde. The cells were analyzed by flow cytometry
in a Cyan (Becton, Dickinson). The percent neutralization for each dilu-
tion was defined as the reduction in the number of GFP-expressing cells in
the test sera compared with the number of positive cells in the VRP con-
trol. The neutralization titer for each serum sample was expressed as the
reciprocal of the highest dilution of serum that neutralized the GFP-VRP
by 50% (NEUT50).
Macaque immunizations and virus challenge. Young adult rhesus
macaques (2 to 8 years of age) seronegative for dengue virus and VEE were
housed at the Caribbean Primate Research Center facilities, University of
Puerto Rico, San Juan, Puerto Rico. All procedures were reviewed and
approved by the Institute’s Animal Care and Use Committee at Medical
Sciences Campus, University of Puerto Rico (IACUC-UPR-MSC), and
performed in a facility accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC) (Animal Welfare
Assurance number A3421; protocol numbers, 7890108, 7890208,
7890209, and 7890210). In addition, steps were taken to ameliorate suf-
fering in accordance with the recommendations of the Weatherall report,
The Use of Nonhuman Primates in Research. For instance, to ameliorate
animal suffering, all procedures were conducted under anesthesia using
ketamine at 10 to 20 mg/kg of body weight intramuscularly (i.m.), as
approved by the IACUC. Anesthesia was delivered in the caudal thigh
using a 23-gauge sterile syringe needle. Continued monitoring was pro-
vided by trained veterinarians at the Animal Research Center. During the
time of the protocol, the animals were under the environmental-enrich-
ment program of the facility, also approved by the IACUC. Vaccines were
formulated in PBS with 1% human serum albumin. The 4 components of
the tetravalent formulation were stored separately at 80°C and mixed
immediately before administration to the animals. Groups of 6 macaques
were immunized by intradermal injection into the upper arm with 0.5
ml/arm of VRP vaccine at a dose of 108 IU for the monovalent DENV3
vaccine and 108 IU of each DENV1, DENV2, and DENV3 component and
2  108 IU of the DENV4 component of the tetravalent formulation.
Macaques received 3 vaccine doses (weeks 0, 7, and 25) in the monovalent
vaccine study or 2 vaccine doses (weeks 0 and 6) in the tetravalent study.
The animals were bled periodically on the day before each immunization
and at 2- or 3-week intervals postimmunization. To determine protective
efficacy, in study week 41 (monovalent study) or week 24 (tetravalent
study), all immunized macaques, along with groups of 4 unvaccinated
control animals, were challenged with 105 PFU of DENV3 Sleman/78
(monovalent study) or 105 PFU of either DENV1 WP, DENV2 NGC,
DENV3 Sleman/78, or DENV4-814669 (tetravalent study). The animals
were bled every day for 10 days postchallenge and on day 28 after chal-
lenge.
Expression and purification of DENV EDIII. Recombinant EDIII
protein fused at the N terminus to maltose binding protein (MBP-EDIII)
was produced as described previously (65). Domains III of the E protein
from DENV2 strain NGC (residues 297 to 399) and DENV3 strain UNC
3006 (residues 295 to 398) were expressed as MBP fusion proteins in
Escherichia coli DH5 (Invitrogen) and purified using amylose resin af-
finity chromatography (NEB) as described previously (65).
Depletions of EDIII-reactive antibodies in macaque serum. MBP-
EDIII and MBP control depletions were done as described previously
(65). Briefly, purified MBP-EDIII and MBP control were equilibrated in
amylose column buffer (NEB). Amylose resin was incubated with 300 g
of recombinant protein in the column buffer. After overnight incubation
at 4°C, the resin was washed 3 times with column buffer and 3 more times
with PBS to remove unbound recombinant protein. After blocking with
5% normal mouse serum (NMS) or 1% bovine serum albumin (BSA) in
PBS, the resin was incubated with 1.5 ml of macaque serum diluted 1:5 in
PBS for 2 h at 37°C. The amylose resin was removed by pelleting, and the
serum, depleted of EDIII-reactive antibodies, was subjected to another 4
or 5 depletion cycles until complete depletion was confirmed by the ab-
sence of EDIII-reactive antibodies by ELISA, using plates coated with
MBP and MBP-EDIII. EDIII and control depleted sera were then tested
for the ability to neutralize DENV in vitro, as described above.
Detection of viremia by immunofocus assay. The presence of virus in
serum samples collected daily for 10 days postchallenge was determined
by incubation on Vero cell monolayers, followed by immune detection of
virus foci using an enzyme-labeled dengue virus MAb, as described pre-
viously (68). Briefly, Vero-81 cells were seeded in 24-well plates, and sub-
confluent monolayers were incubated the next day in triplicate wells with
200 l of each postchallenge serum sample at dilutions of 1:2 and 1:4 or
1:2.5 and 1:5. After a 1-h incubation on a rocker at 37°C, the monolayers
were overlaid with 1 ml 1.0% methylcellulose in Opti-MEM (Gibco) sup-
plemented with 2% fetal bovine serum (FBS) (Cellgro) and antibiotic
mixture (Gibco; Antibiotic-Antimycotic). After 4 to 5 days at 37°C, 5%
CO2, the overlay was removed, and the cells were washed with PBS, fixed
in 80% methanol-1 PBS, and air dried. To visualize the virus foci, the
fixed monolayers were blocked for 10 min with blocking buffer (5% in-
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stant milk in PBS), followed by incubation with anti-flavivirus MAb 4G2
diluted 1:60 in blocking buffer for 1 h at 37°C. The wells were washed with
PBS and incubated with HRP-conjugated goat anti-mouse Ab (Sigma)
diluted 1:500 in blocking buffer for 1 h at 37°C. The plates were washed
once in PBS, and foci were developed by the addition of 150 l/well of
TrueBlue HRP substrate (KPL). Foci were counted on a light box, and
viral titers were calculated by standard methods.
Statistical analysis. Antibody titers were evaluated for statistically sig-
nificant differences by the Mann-Whitney test (INSTAT; GraphPad, San
Diego, CA). A P value of 0.05 was considered significant.
RESULTS
In vitro characterization of dengue virus proteins expressed by
VRP. BHK-21 cell cultures infected with prME-VRP or E85-VRP
or mock infected were harvested at 19 h postinfection and exam-
ined for the expression of dengue virus E protein by SDS-PAGE,
followed by Western blotting. PVDF membranes were probed
with MAb 4G2. Figure 1 shows the results from serotype 3 con-
structs, which are representative of the other three serotypes. The
C-terminally truncated E85 expressed from E85-VRP and the full-
length E expressed from prME-VRP ran at the expected apparent
molecular sizes. E85 showed higher expression levels than full-
length E in both cell lysates and culture media. In the culture
medium lanes, the bands were lighter than those in the cell lysate
lanes, reflecting the smaller fraction (7%) of the total infection
media examined (versus 33% of cell lysates).
To determine whether VRP-expressed E85 formed dimers, se-
rial dilutions of cell lysates and culture supernatants of BHK cells
infected with DENV2 E85-VRP were tested by ELISA for the abil-
ity to bind to mouse MAbs DV2-58 and DV2-46, which bind to
the DENV2 dimer interface (40). Figure 2 shows that VRP-ex-
pressed E85, whether cell associated or secreted, has high reactivity
with both MAbs, indicating their ability to form dimers.
Comparison of the immune responses induced in macaques
by vaccination with VRP expressing different dengue virus an-
tigens and infection with dengue virus. The neutralizing-anti-
body responses to immunization were examined in terms of their
magnitude, breadth, antigenic sites targeted, and ability to protect
from DENV3 challenge. In addition, we compared the vaccine-
induced antibody responses to those induced by the DENV3 chal-
lenge of naïve animals as a surrogate for natural infection.
Monovalent VRP vaccines induce neutralizing-antibody re-
sponses and protection from challenge. In this monovalent vac-
cine study, two groups of 6 macaques each were immunized with
3 doses of 108 IU of DENV3 prME-VRP or DENV3 E85-VRP at
study weeks 0, 7, and 25. At 14 weeks after the last immunization,
the 12 immunized monkeys and 4 unimmunized controls were
challenged with DENV3. Sera collected periodically after each of 3
immunizations with DENV3 prME-VRP or E85-VRP were ana-
lyzed for neutralizing antibodies to DENV3. Table 1 shows the
Neut50 titers for each individual macaque after the first, second,
and third immunizations and the geometric mean titer (GMT) for
each vaccine group. The E85 configuration resulted in signifi-
cantly higher neutralizing-antibody titers to the serotype 3 virus
than prME. Seven weeks after dose 1, macaques immunized with
prME-VRP did not show detectable neutralizing-antibody titers,
while 5 of 6 animals immunized with E85-VRP had Neut50 titers
Cell Lysates          Culture Media
M   prME  E85        M   prME   E85
E
E85
FIG 1 In vitro expression of DENV E protein in VRP-infected BHK cells.
BHK-21 cells grown in 24-well plates were mock infected or infected at an MOI
of 10 with VRP expressing DENV3 prME or E85. Culture media and cell lysates
in each well were harvested at 19 h postinfection and analyzed for the presence
of the E protein by nonreducing SDS-PAGE, followed by Western blotting.
Approximately 33% of the cell lysate and 7% of the culture medium per well
was loaded in each lane. Electrophoresed proteins were transferred onto poly-
vinylidene fluoride membranes and probed with mouse MAb 4G2. Following
incubation with goat anti-mouse IgG-HRP, membranes were developed using
ECL substrate. M, mock infected; prME, DENV3 prME-VRP; E85, DENV3
E85-VRP. Bands migrating at the expected sizes corresponding to full-length E
protein (E) and C-terminally truncated 85% of E (E85) are indicated.
FIG 2 E85 binds to MAbs that recognize only the interface of adjacent E dimers. Mouse MAbs DV2-58 and DV2-46, which bind to the DENV2 dimer interface,
were used to coat ELISA plates. Serially diluted supernatants and cell lysates from DENV2 E85-VRP or mock-infected Vero cells harvested 24 h p.i. were then
added to the wells in duplicate. E85 binding was detected with EDIII-reactive human MAb 1M23, followed by incubation with alkaline phosphatase-conjugated
goat anti-human antibody and p-nitrophenyl phosphate substrate. The data points represent mean OD405  standard deviations (SD). dln, dilution.
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equal to or above 20. Three weeks after the second dose, all the
animals in both groups had a significant increase in titer, with
GMTs of 49 for prME and 214 for E85. When measured 18 weeks
after the second dose, Neut50 titers had dropped; however, all
E85-VRP-immunized monkeys had titers above 20, with a GMT
of 52, while 3 out of 6 prME-VRP-immunized monkeys had titers
above 20. After a third dose, the titers increased in both groups,
and at the time of challenge, 14 weeks after the last immunization,
4 of 6 macaques immunized with the prME construct had modest
titers ranging from undetectable (20) to 32, while all macaques
immunized with E85 had titers ranging from 48 to 280, with a
GMT of 106 (Table 1). The improved immunogenicity of E85 over
prME was also demonstrated for serotype 2 in a smaller experi-
ment with a similar immunization schedule but only two ma-
caques per group. After the first dose, only E85-VRP-immunized
animals had detectable neutralizing-antibody titers (a Neut50 of
40 for each animal). After the second dose, E85-VRP induced
titers of 160 and 320, while prME-VRP titers were 20 and 80. After
the third dose, the E85-VRP titers were 320 and 320, while the
prME titers were 40 and 40.
To determine the abilities of the vaccine candidates to protect
from infection, vaccinated macaques, along with 4 unvaccinated
controls, were challenged with 105 PFU of DENV3 strain Sle-
man/78 live virus at 14 weeks after the last immunization. Because
macaques do not develop signs of disease after DENV infection
but do develop a low-level viremia during the 10 days immediately
following the challenge, protective efficacy was determined by the
ability of the vaccine to reduce the duration and titer of peak
viremia after challenge. Serum viremia was determined by immu-
nofocus assay in samples collected daily for 10 days. Table 2 shows
the titers of DENV, expressed as log10 focus-forming units (FFU)/
ml, in the serum of each macaque. All the unvaccinated control
macaques had viremia between days 2 and 8 postchallenge, with
titers ranging from 2.57 to 3.89 log10 FFU/ml. Monkeys immu-
nized with prME-VRP were partially protected. Four out of 6 had
no detectable virus, and the other 2 showed viremia of shorter
duration. In contrast, all the animals immunized with E85-VRP
were protected, as indicated by undetectable viremia (limit of de-
TABLE 1 Neut50 against DENV serotype 3
a after the 1st, 2nd, and 3rd

















AJ97 20 80 23 32
AH06 20 38 22 20
M654 20 46 20 24
M745 20 46 20 20
72V 20 58 22 21
98O 20 35 20 20
GMTd 5 49 11 14
DENV3
E85-VRPc
AI15 51 244 84 280
AH52 20 70 29 58
AM41 34 425 134 203
M635 20 176 50 61
M636 30 161 42 146
M630 28 467 30 48
GMT 23 214 52 106
a The DENV3 used in the neutralization assay was reference strain CH53489.
b Dose 1, week 0; dose 2, 7 weeks after dose 1; dose 3, 18 weeks after dose 2.
c Macaques were immunized by intradermal injection in the upper arm with 108 IU of
VRP vaccine.
d For calculations of GMTs, titers of 20 were assigned a value of 5.
e ID, identifier.
f Neut50 titers are significantly different between prME-VRP and E85-VRP groups after
doses 1, 2, and 3 (P  0.05 at every time point by Mann-Whitney test).






Viremiab (log10 FFU/ml) on day postchallenge: Neut50 anti-DENV3







ID3  3.50 3.60 3.40 3.00      20 235
IE9   2.64 2.57 2.87 3.38 3.59 2.79   20 357
6D5  3.77 3.89 3.09 2.87      20 180
50T      3.00 2.69    20 55
DENV3
prME-VRP
AJ97           32 20,480
AH06           20 4,321
M654           24 2,477
M745           20 4,125
72V   3.17 2.69       21 17,362
98O   2.57 2.94       20 3,272
DENV3
E85-VRP
AI15           280 12,550
AH52           58 20,480
AM41           203 9,954
M635           61 20,480
M636           146 11,981
M630           48 20,480
a Monkeys were challenged 14 weeks after dose 3.
b Viremia was quantified by immunofocus assay, which measured infectious virus on Vero cells. , below the level of detection of 10 FFU/ml.
c Prechallenge Neut50 titers were determined on the day of challenge.
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tection, 10 FFU/ml). The last 2 columns in Table 2 show Neut50
titers before challenge and 28 days after challenge. From these
results, it was not possible to determine a minimum prechallenge
titer that would correlate with protection. While the prechallenge
titers of the 2 animals in the prME-VRP group that showed de-
tectable postchallenge viremia (macaques 72V and 980) were at or
below the level of detection, other macaques with low titers rang-
ing from 20 to 32 showed no postchallenge viremia. All the
vaccinated animals had a very strong recall response after the chal-
lenge, with Neut50 titers that were 36 to 121 times higher than those in
the unvaccinated controls at this time point. This suggests that the
vaccine did not induce sterilizing immunity and also indicates the
strong priming effect of the VRP vaccine. The convalescent-phase
serum neutralization titers in the unvaccinated control animals at 28
days postinfection ranged from 55 to 357. These titers are comparable
to those induced after 2 doses of E85-VRP immunization, which
ranged from 70 to 467 at 21 days after the second dose.
In summary, both DENV3-VRP vaccines induced neutralizing
antibodies and protection from DENV3 challenge-induced
viremia. However, E85-VRP induced a faster and stronger neu-
tralizing-antibody response, which was consistent with better pro-
tection from challenge than prME-VRP. In addition, our data
indicate that the priming afforded by the VRP vaccines is suffi-
cient, not only to significantly reduce the replication of challenge
virus, but also to prime a strong anamnestic response consistent
with long-term immunity.
Breadth of the neutralizing-antibody response. To further
characterize the quality of the antibody response induced by
DENV3 prME-VRP, E85-VRP, and live DENV3 infection, we
measured the induction of serotype cross-reactive neutralizing
antibodies. The virus strains used in the neutralization assay were
WHO reference strains representing each serotype, as described in
Materials and Methods. Neutralization titers to all 4 serotypes
were determined in sera collected 3 weeks after the second VRP
immunization. DENV3 prME-VRP preferentially induced titers
to serotype 3 virus, but also induced detectable neutralizing-anti-
body titers to the heterologous serotypes in all the animals, with
Neut50 GMTs of 23, 39, 58, and 24 to serotypes 1, 2, 3, and 4,
respectively (Fig. 3A). In contrast, E85-VRP immunization in-
duced strong serotype 3-specific antibodies, with undetectable
neutralizing antibodies to the other three serotypes (Fig. 3B). The
breadth of the antibody response after live DENV infection was
also examined as a control representing live-virus immunization/
infection. Macaque sera collected 4 weeks after infection with
DENV3 in unimmunized control animals were able to neutralize
the homologous serotype 3 virus with high Neut50 titers but also
had cross-reactive antibodies with neutralizing activity to serotype
1, 2, and 4 viruses (Fig. 3C).
Due to the serotype-specific nature of the neutralizing-anti-
body response to the E85-VRP vaccine, and based on recent ob-
servations indicating that genotypic variation within each sero-
type may be important in protective immunity (37, 42, 69, 70), we
examined the influence of intraserotype genotypic differences on
vaccine performance. For this, we tested the ability of DENV3
E85-VRP macaque sera to neutralize DENV3 strains representing
genotypes I to IV (Fig. 4). We found that the vaccine-induced
antibodies were able to neutralize with equal potency viruses from
the vaccine strain genotype (GIII) and from the other genotypes
(GI, GII, and GIV).
In summary, macaque antibody responses to prME-VRP and
live virus were characterized by dominant serotype-specific neu-
tralizing antibodies and lower but detectable cross-reactive anti-
bodies to the other serotypes. In contrast, antibodies to E85-VRP
neutralized only serotype 3 virus isolates, including strains repre-
senting all DENV3 genotypes (I to IV).
FIG 3 Serotype-specific and cross-reactive neutralizing-antibody titers (Neut50) in macaques after monovalent DENV3-VRP immunization and after DENV3
infection. Three weeks after dose 2, sera from macaques immunized with DENV3 prME-VRP (A) or DENV3 E85-VRP (B), and 4 weeks postchallenge, sera from
unimmunized control macaques (C) were tested for neutralization against DENV reference strains from serotypes 1, 2, 3, and 4: DENV1, West Pac 74; DENV2,
S-16803; DENV3, CH53489; DENV4, TVP-360 (DV1 to DV4, respectively). Each symbol represents the Neut50 titer of an individual macaque. The GMT is
represented by a horizontal bar. Dashed lines, lower limit of detection. Samples with Neut50 values below 10 were assigned a value of 5.
FIG 4 Breadth of serotype-specific neutralizing-antibody response after mon-
ovalent DENV3 (GIII) E85-VRP immunization. Six weeks after dose 2, sera
from DENV3 E85-VRP-immunized animals were tested for neutralization
against strains from different genotypes within serotype 3: DENV 3043 for GI,
CH53489 for GII, UNC 3002 for GIII (homologous to the vaccine strain), and
DENV3PR77 for GIV. Each symbol represents the Neut50 titer of an individual
macaque. The GMT is represented by a horizontal bar. Dashed lines, lower
limit of detection.
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Contribution of EDIII-binding antibodies to the neutraliz-
ing response. Previous studies have demonstrated that mice chal-
lenged with DENV develop high levels of neutralizing antibodies
that bind to EDIII, whereas humans exposed to natural dengue or
West Nile virus infections develop neutralizing-antibody re-
sponses that mainly target epitopes on EDI and EDII (47, 65, 71,
72). The major antigenic sites targeted by neutralizing antibodies
induced by the VRP vaccines in macaques were compared to those
induced by virus infection with respect to EDIII specificity.
DENV3 EDIII-binding antibodies were depleted from the sera of
DENV-immune macaques using recombinant EDIII-MBP or
control MBP protein bound to amylose resin beads. Depletion
was monitored by EDIII-MBP binding ELISA, and complete de-
pletion (the ELISA OD at 405 nm [OD405] was 0.1 at 1:10 serum
dilution) was confirmed after 6 depletion cycles.
Figure 5 shows Neut50 titers of control MBP-depleted and
DENV3 EDIII-MBP-depleted sera from DENV-immune ma-
caques. In sera collected after two immunization doses with
DENV3 prME-VRP, neutralizing-antibody titers did not change
after EDIII-binding antibodies were depleted (Fig. 5A). In con-
trast, sera from DENV3 E85-VRP macaques at the same time
point showed a significant reduction in neutralization titers after
EDIII-binding antibodies were depleted, suggesting that a large
proportion of neutralizing antibodies were directed to EDIII (Fig.
5B). Control monkeys infected with DENV3 had neutralization
titers that did not change after depletion of EDIII-binding anti-
bodies (Fig. 5C). This was consistent with reports that EDIII an-
tibodies contribute little to the neutralizing response after a natu-
ral infection in humans (48, 65) and suggested that DENV
infection in macaques stimulates a dengue virus-specific antibody
repertoire similar to that in humans. These depletion studies also
suggest that E antigen can induce a qualitatively different antibody
response, depending on its configuration, and that the quality of
the immune response elicited by prME-VRP more closely resem-
bles the immune response after a natural DENV infection than
that elicited by E85-VRP.
Tetravalent VRP using E85 antigen configuration in ma-
caques. We chose in this study to construct and evaluate a
tetravalent vaccine expressing the E85 configuration. Our ra-
tionale was to construct a tetravalent formulation in which
each serotype component would induce strong serotype-spe-
cific neutralizing antibodies and in which EDIII epitopes for
each serotype would make a significant contribution. In addi-
tion, the absence of prM would reduce the fraction of weakly
neutralizing, cross-reactive, potentially enhancing antibodies
that map to prM.
Neutralizing-antibody responses. To assess whether a tet-
ravalent cocktail of VRP expressing E85 from each serotype would
induce a balanced immune response against all 4 serotypes, 16
young adult rhesus macaques were immunized at 0 and 6 weeks
with a cocktail containing 1  108 IU DENV1 E85-VRP, 1  108
IU DENV2 E85-VRP, 1  108 IU DENV3 E85-VRP, and 2  108
IU DENV4 E85-VRP. The vaccine components were mixed at a
ratio of 1:1:1:2 based on results in mice, where we found that
DENV4 E85-VRP, as a monovalent vaccine and in a tetravalent
cocktail with equal doses of each serotype, was less immunogenic
than the other 3 serotypes. Adjusting the dose of DENV4 E85-VRP
in the tetravalent cocktail resulted in higher DENV4 neutraliza-
tion titers and more balanced responses (White, unpublished).
The vaccine regime in this tetravalent VRP study was reduced to
two instead of three immunizations, since in the monovalent
study, two doses were sufficient to induce 100% seroconversion.
Table 3 shows the 50% neutralization titers of individual ma-
caques and GMTs after the first and second doses and before chal-
lenge. Preimmunization titers were 10 in all animals tested (data
not shown). After one dose, 13 of 16 macaques had detectable
neutralizing antibodies to at least 3 serotypes, with Neut50 GMTs
of 20, 41, 10, and 34 to serotypes 1, 2, 3, and 4, respectively. After
the second immunization, all 16 macaques had neutralizing-anti-
body titers against all 4 serotypes, with GMT titers of 283, 446, 202,
and 284 against serotypes 1, 2, 3, and 4, respectively (Table 3).
Although there was animal-to-animal variation in the titers, all
animals had robust neutralizing-antibody titers against all 4 sero-
types after 2 doses, with titers to DENV2 being higher than those
against other serotypes in 9/16 animals. Although the titers had
dropped by the time of challenge, all the macaques had detectable
FIG 5 Contribution of DENV3 EDIII-binding antibodies to neutralization. Macaque immune sera were depleted of DENV3 EDIII-binding antibodies by
incubation with EDIII-MBP or control MBP protein bound to amylose beads. Neutralizing-antibody titers to DENV3 were determined in control-depleted and
EDIII-depleted sera for each animal. The horizontal bars represent geometric mean titers for each depletion group. (A) Sera from macaques 3 weeks after the
second immunization with DENV3 prME-VRP. (B) Sera from macaques 3 weeks after the second immunization with DENV3 E85-VRP. (C) Sera from macaques
4 weeks after DENV3 infection. Complete depletion of EDIII-reactive antibodies was confirmed by EDIII ELISA. The data are representative of one of three
experiments. **, P  0.05 by the Mann-Whitney test.
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neutralizing antibodies against all 4 serotypes, with GMTs of 71,
88, 41, and 97 to serotypes 1, 2, 3, and 4, respectively.
The bottom row in Table 3 shows the percentage of animals
with neutralizing antibodies to each serotype after the first and
second immunizations and on the day of challenge. After one
dose, 81% of the animals had neutralizing antibodies to 3 or more
serotypes, and 56% had neutralizing antibodies to all 4 serotypes.
After the second dose, all the animals had neutralizing antibodies
to all 4 serotypes. Four months later, although titers had waned in
some animals, 16 out of 16 retained neutralizing antibodies
against all 4 serotypes.
As monovalent DENV3 E85-VRP vaccination induced pre-
dominantly serotype-specific, EDIII-targeted neutralizing anti-
bodies, studies were done to test if the tetravalent vaccine stimu-
lated 4 separate populations of neutralizing antibodies that bound
to EDIII of each serotype. Immune sera from monkeys that re-
ceived the E85 VRP tetravalent vaccine were depleted of DENV3
EDIII-binding antibodies and tested for the ability to neutralize
each serotype (Fig. 6). Depletion of DENV3 EDIII-reactive anti-
bodies resulted in a large decrease in DENV3 neutralization, a
slight decrease in DENV1 neutralization, and no change in the
ability to neutralize serotypes 2 and 4. These results suggest that as
in the monovalent DENV3 E85-VRP vaccine, the DENV3 E85-
VRP component in the tetravalent vaccine stimulates a distinct
population of EDIII-reactive antibodies with serotype-specific
neutralization. It is likely that the tetravalent vaccine will elicit
four monovalent EDIII responses. However, since we depleted
only with DENV3 EDIII, we cannot conclude unequivocally that
the other 3 components of the immune response are also specific.
The reduced ability of the DENV3 EDIII-depleted immune sera to
TABLE 3 Neutralizing-antibody titers against DENV serotypes 1 to 4 in macaques after immunization with 2 dosesa of tetravalent E85-VRPb
Macaque ID
Neut50 against:
6 wk after dose 1 2 wk after dose 2 18 wk after dose 2 (prechallenge)
DENV1 DENV2 DENV3 DENV4 DENV1 DENV2 DENV3 DENV4 DENV1 DENV2 DENV3 DENV4
2H9 10c 22 10 23 274 735 212 292 112 67 36 101
9H4 50 84 35 48 359 1516 297 264 29 73 93 48
8E7 10 10 10 10 85 63 154 102 53 24 81 23
6F5 32 38 10 36 201 337 91 89 44 106 58 35
6E1 25 18 25 27 187 167 128 73 22 50 11 56
6B1 11 10 15 23 142 55 97 63 23 17 14 24
1C4 116 101 38 153 395 938 218 726 207 97 13 140
9B4 10 15 10 10 370 306 168 337 44 174 168 192
3C1 13 13 11 31 300 378 219 462 35 40 24 48
4F3 77 84 35 88 469 993 341 223 48 331 30 323
4C7 12 10 16 94 308 232 134 660 61 56 14 203
0G6 64 29 10 97 215 454 170 684 73 101 19 176
3G8 176 111 77 58 674 1096 530 278 232 193 657 215
BA35 30 77 77 38 296 619 276 522 453 170 38 176
AZ99 61 97 35 70 458 1706 313 445 186 329 58 143
BA10 88 35 44 97 307 865 241 778 80 88 44 134
GMT 28 29 18 40 283 446 202 284 71 88 41 97
% Seroconversiond 81 81 69 88 100 100 100 100 100 100 100 100
a Dose 1, week 0; dose 2, 6 weeks after dose 1; challenge, 18 weeks after dose 2.
b TV-E85-VRP was formulated by mixing 1  108 IU each of DENV1-, -2-, and -3-E85-VRP and 2  108 IU of DENV4-E85-VRP.
c Samples with Neut50 titers lower than 10, the lowest serum dilution tested, were assigned a titer of 5 for calculation of the GMT.
d Seroconversion was defined as a Neut50 titer of 10.
FIG 6 Contribution of DENV3 EDIII-binding antibodies to neutralization in macaques immunized with tetravalent DENV E85-VRP. Macaque immune sera
were depleted of DENV3 EDIII-binding antibodies by incubation with EDIII-MBP or control MBP protein bound to amylose beads. Neutralizing-antibody titers
to each serotype were determined. (A) Anti-DENV3. (B) Anti-DENV1. (C) Anti-DENV2. (D) Anti-DENV4. The horizontal bars represent geometric mean titers
for each depletion group. Complete depletion of EDIII-reactive antibodies was confirmed by EDIII ELISA. *, P 	 0.0286, and **, P 	 0.0031 by the Mann-
Whitney test. Within each graph, each symbol type refers to the same animal.
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neutralize DENV1 suggests that the vaccine targets subcomplex
cross-reactive epitopes on EDIII and is consistent with the obser-
vation that strains from serotypes 1 and 3 are closer phylogeneti-
cally to each other than to serotypes 2 and 4 (92).
Protection from postchallenge viremia after 2 doses. To de-
termine whether the tetravalent VRP vaccine would protect
against infection with each DENV serotype, the 16 immunized
macaques were randomly assigned to 4 challenge groups (4 ani-
mals/group). Another 16 unimmunized macaques were divided
into 4 challenge groups (4 animals/group) and used as controls.
This resulted in four challenge groups of 8 macaques each (4 im-
munized and 4 unimmunized). The macaques in groups 1, 2, 3,
and 4 were challenged in week 18 postboost with 105 FFU of
DENV1, DENV2, DENV3, and DENV4, respectively. The animals
were bled daily for 10 days and then again on day 28. Table 4 shows
DENV titers in the serum of each animal during the 10 days fol-
lowing challenge. The values represent log10 FFU/ml as deter-
mined by immunofocus assay. Of the 8 macaques challenged with
DENV1, the 4 controls had viremia lasting from 3 to 5 days, with
peak titers of 2.96, 2.15, 2.89, and 2.65 log10 FFU/ml. Two of the 4
immunized macaques had no detectable viremia, while the other 2
animals showed low-level viremia (1.52 and 1.23 log10 FFU/ml)
that lasted 1 day. Of the macaques challenged with DENV2, all the
controls had 2 to 6 days of viremia, with peak titers ranging from
2.09 to 2.58 log10 FFU/ml. Three of the immunized monkeys had
low-level viremia that lasted 1 or 2 days. In the groups challenged
with DENV3, all the control macaques had viremia (peak titers
between 1.52 and 3.01) lasting 2 to 5 days, while no viremia was
detected in any of the vaccinated animals at any time point. The
same was the case for animals challenged with DENV4, where all
controls had viremia with peak titers ranging between 1.83 and
2.35 and 3 to 7 days duration, while the 4 immunized animals had
no detectable viremia (Table 4).
Prechallenge and postchallenge Neut50 titers against the chal-
lenge viruses are shown in Table 4 for each animal. There were 5
immunized macaques that had detectable postchallenge viremia.
The three with higher prechallenge Neut50 titers against the chal-
lenge virus (2H9, 9B4, and BA35) had very low viremia (at the
level of detection) that lasted only 1 day. Another macaque with
breakthrough viremia (6B1) had a homologous Neut50 titer of 23
and low viremia lasting 1 day. Macaque 6E1 had a prechallenge
Neut50 titer of 50 and peak viremia of 2.18.
To measure the ability of the vaccine to induce a strong anam-
nestic response, Neut50 titers were measured at day 10 postchal-





Viremiaa (log10 FFU/ml) on day postchallenge: Neut50 titer
b
1 2 3 4 5 6 7 8 9 10 Prechallenge
Day 10
postchallenge
6B1 DENV1 Immunized   1.52        23 19,953
1C4           207 13,146
2H9  1.23         112 13,146
3G8           232 14,423
4E6 Controls 2.09 2.96 2.22 0.90       10 446
IF5 1.23 1.40  1.52 2.15 1.23     10 367
5E5 2.35 2.89 2.45 1.23 1.23      10 711
2F6  2.65 2.45 1.23  0.90     10 134
6F5 DENV2 Immunized           106 
20,480
6E1  2.18 1.83        50 
20,480
9B4  1.23         174 
20,480
BA35   1.23  0.90      170 
20,480
3F3 Controls  2.09 1.40 1.40 0.90 1.23 0.90    10 608
9E2  1.52 1.23 1.40 1.52 2.12 2.28    10 413
BC19  2.22 2.07 1.23       10 1,126
OHI  2.58 1.40        10 1,590
8E7 DENV3 Immunized           81 5,201
4F3           30 10,921
3C1           24 19,046
9H4           93 4,996
2G5 Controls  1.23 3.01 2.67 2.12 2.54     10 104
3H8   0.90 1.52 1.40 1.70     10 263
4H9   2.41 1.62 1.23 1.40     10 225
8F7   1.52 1.23       10 1017
4C7 DENV4 Immunized           203 3,272
0G6           176 10,426
AZ99           143 2,433
BA10           134 13,146
9G9 Controls 2.09 1.52 1.23        10 233
BD57 2.22 2.09 1.83        10 353
6F8 2.35 2.07 1.23        10 185
6G0 0.90 1.83 1.23 1.30 1.70 1.40 1.23    10 46
a Viremia was quantified by immunofocus assay, which measured infectious virus on Vero cells. , below the level of detection of 8 FFU/ml.
b Neut50 titers against the serotype of the challenge virus.
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lenge. Pre- and postchallenge Neut50 titers against the homolo-
gous challenge virus are shown in Table 4 for each unvaccinated
and TV-E85-VRP-vaccinated animal in the study. There is a
strong recall response in all vaccinated animals at only 10 days
after challenge with each DENV serotype. In contrast, Neut50
GMTs against the challenge virus in unvaccinated controls were
moderate, 353 against DENV1, 656 against DENV2, 281 against
DENV3, and 163 against DENV4. We also measured postchal-
lenge neutralization titers to the heterologous serotypes and found
a robust recall response, as well. After DENV1 challenge, Neut50
GMTs against serotypes 2, 3, and 4 were 8,174, 1,251, and 993,
respectively. After challenge with DENV2, Neut50 GMTs against
serotypes 1, 3, and 4 were 4,632, 1,268, and 1,591, respectively.
After challenge with DENV3, Neut50 GMTs against serotypes 1, 2,
and 4 were 952, 2,187, and 457, respectively. Finally, after chal-
lenge with DENV4, Neut50 GMTs against serotypes 1, 2, and 3
were 243, 1,099, and 279, respectively. These results indicate that
although the vaccine did not induce sterilizing immunity, it
primed a strong anamnestic response, not only to the serotype of
the challenge virus, but also to the other 3 serotypes.
Anti-vector immunity. VRP are VEE replicon vectors pack-
aged into particles that have VEE glycoproteins on their surfaces.
Although these are single-replication-cycle vectors, anti-VEE an-
tibodies are induced. Our group has shown that mice that have
been immunized with VRP expressing one antigen can mount an
immune response to a second VRP-expressed antigen that is no
different from that of mice that have not been exposed to VRP
before. This suggests that in mice, antivector immunity does not
interfere with mounting a good immune response to the expressed
antigen (N. L. Davis, personal communication). To determine
whether this is also the case in macaques, we measured the anti-
VEE neutralizing antibodies after the first and second vaccine
doses in macaques immunized with prME-VRP or E85-VRP (Fig.
7A). Seven weeks after the first dose, 11 out of 12 macaques had
anti-VEE titers ranging from undetectable (10) to 893, with a
GMT of 61. Two macaques had undetectable anti-VEE titers. Six
weeks after the second dose, the anti-VEE Neut50 titers ranged
from 505 to 2,074, with a GMT of 932, which was significantly
higher than the GMT after the first immunization. We then cal-
culated the fold increase in the anti-DENV neutralizing antibodies
for each macaque after the boost and plotted the values against the
anti-VEE titer at the time of the boost (Fig. 7B). We found that
there was no correlation between anti-vector antibody titers and
the fold increase of anti-DENV neutralizing titers between the
prime and the boost doses, suggesting that anti-vector antibodies
do not significantly interfere with the ability of a second dose to
boost.
DISCUSSION
There is an urgent need to accelerate the development of second-
generation dengue vaccine candidates. This study demonstrates in
an NHP model that the VRP vector is a strong next-generation
dengue vaccine platform that provides tetravalent neutralizing-
antibody responses after 2 doses and protective efficacy from chal-
lenge-induced viremia. The study provides an in-depth evaluation
of two VRP-derived dengue vaccine candidates, including a com-
parison of the qualitative parameters of the antibody responses
induced after vaccination versus virus infection.
The first results of a dengue vaccine efficacy study were pub-
lished recently (19), and they underscore the need not only to
accelerate the development of alternative dengue vaccine plat-
forms to LAV, but also to further evaluate current vaccine candi-
dates in preclinical and clinical settings to better characterize
quantitatively and qualitatively the vaccine-induced immune re-
sponses in a search for better immune correlates of protection.
The LAV vaccine candidate used by Sanofi Pasteur, CYD-TDV,
was safe in dengue virus-naïve areas and areas of endemicity and
induced neutralizing antibodies against all 4 serotypes in most
subjects after 3 doses administered in the course of 1 year (18).
However, results from a phase 2b proof-of-concept study in Thai-
land showed unexpectedly low (30%) and insignificant efficacy
(19). Surprisingly, there was no measurable efficacy against sero-
type 2, which was the prevalent serotype during the study.
Whether ongoing larger phase 3 trials in different geographic lo-
cations will show improved efficacy remains to be determined.
Two other tetravalent LAV candidates in earlier phases of clinical
testing, NIAID’s TetraVax-DV and Inviragen’s DENVax, have re-
ported high seroconversion rates in dengue virus-naïve volunteers
after only 1 or 2 immunizations (A. Durbin, presented at the
American Society of Tropical Medicine and Hygiene 61st annual
meeting, Atlanta, GA, 2012; J. E. Osorio, presented at the Third
Panamerican Dengue Research Network Meeting, Cartagena, Co-
lombia, 2012). Whether these LAV vaccine candidates will show
improved efficacy remains to be demonstrated.
FIG 7 Effect of anti-vector immunity on the ability of the second VRP dose to boost DENV neutralizing antibodies. Macaques were immunized with 108 IU
DENV3 prME or E85-VRP at 0 and 7 weeks. (A) At 7 weeks postprime and 6 weeks postboost, animals were bled and neutralizing-antibody titers were
determined against VEE. Each symbol represents the Neut50 titer of an individual macaque. The GMT is represented by a horizontal bar. (B) For each monkey,
the anti-VEE Neut50 titer at the time of the boost is plotted against the fold increase of the anti-DENV3 Neut50 titer, calculated as the ratio between the titer at
3 weeks after the second dose and 7 weeks after the first dose. (Individual titers are listed in Table 1.)
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Nonpropagating VEE replicon particles expressing two config-
urations of DENV3 E antigen, prME and E85, successfully immu-
nized and protected macaques against dengue virus, while anti-
vector antibodies did not interfere with a booster immunization.
Compared to prME, expression of soluble E85 induced neutraliz-
ing antibodies faster and to higher titers, and E85 was more pro-
tective in DENV challenge studies. The differences in the magni-
tude and quality of the neutralizing-antibody responses between
DENV3 prME and E85 antigens may have resulted from differ-
ences in levels of protein expression and secretion, differences in
the quaternary organization of E protein (as soluble dimers or as
recombinant subviral particles), and/or whether prM was present.
The possible contribution of differences in protein levels was sug-
gested when E protein expression was examined in BHK cells 19 h
after VRP infection by Western blotting. We found higher levels of
E protein in both cell lysates and culture media of E85-VRP-in-
fected cells than in cells infected with prME-VRP (Fig. 1), suggest-
ing that when equivalent VRP doses are administered, the effective
antigen dose may be higher in the E85 configuration.
The quaternary organization of flavivirus E protein has an im-
pact on its antigenic structure (73). In this study, we compared the
antibody responses induced by infectious DENV virions, recom-
binant DENV subviral particles (prME), and soluble E dimers
(E85). Coexpression of prM and E of dengue virus and other fla-
viviruses using heterologous expression systems results in the as-
sembly of recombinant subviral particles (74–79). These subviral
particles are smaller than dengue virus virions, have an icosahe-
dral symmetry of T 	 1 instead of T 	 3, and may display E
proteins with different organizations. However, like virions, they
may exist as mature or partially immature particles, depending on
the extent of prM cleavage (80, 81). Since we were able to detect E
and prM in the supernatant of BHK cells infected with prME-
VRP, it is likely that these antigens were present as subviral, par-
tially immature particles. On the other hand, VRP-expressed E85
was secreted as a soluble protein. The crystal structure of E protein
demonstrates that the soluble ectodomain forms a dimer in a
head-to-tail orientation (36). We used mouse MAbs that bind to
the interface between dimers (40) to determine if E85 expressed
from VEE replicons formed dimers. As depicted in Fig. 2, dimer
interface MAbs recognized DENV2 E85 protein. These results in-
dicate that at least some, if not all, DENV2 E85 forms dimers. As
we have only DENV2 dimer interface antibodies, we could not use
this approach to confirm whether DENV1, -3, and -4 also form
dimers.
The focus of our study on antibody targeting specificities was
EDIII because this region has been identified as a major target of
mouse monoclonal antibodies with strong neutralization capaci-
ties (41, 43, 82–85). Interestingly, recent studies with human im-
mune sera and monoclonal antibodies indicate that E protein
epitopes on EDI and EDII and quaternary epitopes formed by the
tight packing of E proteins on the surface of the virus are the main
targets of antibodies induced by natural DENV infection of hu-
mans (48, 50, 65, 86). Our results here demonstrate that macaques
infected with DENV also develop strongly neutralizing antibodies,
most of which are not directed against EDIII. Thus, natural infec-
tions with DENV in both humans and nonhuman primates seems
to lead to antibody responses dominated by non-EDIII-binding
antibodies.
In contrast to infection, VRP vaccination with E85 antigen
stimulated neutralizing antibodies that mainly targeted epitopes
on EDIII of the vaccine virus serotype only. Our results indicate
that monovalent vaccination stimulated EDIII antibodies that
bound and neutralized the vaccine serotype, but not the other 3
serotypes. In the tetravalent formulation, the vaccine also appears
to stimulate separate populations of type-specific EDIII antibod-
ies that neutralize each serotype. It is unknown why E proteins
expressed in the context of a natural DENV infection and VEE
replicons expressing E85 stimulate qualitatively different popula-
tions of neutralizing antibodies. It has been reported that PrM/M
harbors immunodominant epitopes that induce cross-reactive,
weakly neutralizing or nonneutralizing antibodies that are not
necessary for protection and that may function as decoys to the
immune system (46). The absence of prM/M in the E85-VRP vac-
cine might have helped EDIII become more visible immunologi-
cally. In the E85 construct, the EDII fusion loop epitope should be
available. We suspect that the E85-VRP vaccine induces a lot of
cross-reactive fusion loop antibodies, but it is well documented
that these antibodies are weakly neutralizing compared to EDIII
antibodies. In fact, we recently reported that removal of all cross-
reactive antibodies (which include fusion loop antibodies) from
dengue virus immune sera had no effect on the ability of the sera to
neutralize dengue virus, indicating that most of the neutralizing
antibodies target the type-specific epitopes and not conserved re-
gions, like the fusion loop (49). The similarity in the antibody
repertoire after virus infection in NHPs to that in humans suggests
that the human antibody response to E85-VRP vaccination could
be expected to be, as seen in NHPs, dominated by EDIII specific-
ities and therefore different from that induced by live attenuated
virus platforms currently in clinical trials.
The antigen specificities targeted by LAV vaccines have not
been reported. One can speculate that LAV-induced specificities
may be similar to those induced after natural infection. There is a
chance that, due to attenuation, LAV vaccines as a class will not
induce enough of the type of immunity required for protection.
Therefore, it seems important to accelerate the development and
thorough characterization of other vaccine platforms, like the one
presented in this paper, as additional approaches. Furthermore,
heterologous prime-boost regimes with LAV and E85-VRP vac-
cines may enhance the response to strongly neutralizing, type-
specific EDIII epitopes, which may be underrepresented after a
LAV vaccination.
A vaccine with narrow serotype specificity might result in fail-
ure of the vaccine to protect against diverse strains within the
serotype. This was a concern, since recent studies showed that
monoclonal antibodies that bind to epitopes in EDIII may show
variable or limited neutralization of other genotypes (37, 42). The
E85-VRP vaccine, derived from DENV3 UNC 3001 genotype III,
was able to neutralize strains from genotypes I, II, and IV within
serotype 3. Although E85-VRP vaccines from serotypes 2, 3, and 4
were not tested independently as monovalent vaccines in this
study, we predict that the pattern of inter- and intraserotype neu-
tralizing antibodies will be similar to that seen for DENV3.
After primary infection in humans, cross-reactive antibodies
have been implicated in enhancing a secondary infection with a
different serotype (87, 88). Waning serotype cross-reactive neu-
tralizing antibodies can facilitate virus entry via the Fc receptor
and predispose to severe disease via ADE (89). Similarly, priming
immunizations with a LAV induced serotype cross-reactive neu-
tralizing antibodies while failing to induce specific antibodies to
all four serotypes simultaneously. A further complicating effect of
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these cross-reactive neutralizing antibodies is that they interfere
with a booster live immunization unless the booster is given 4 to 6
months later (14, 64). The interval between prime and boost thus
becomes a period in which vaccinees may be more vulnerable to
severe dengue virus than if they did not receive the vaccine in the
first place. If a significant proportion of persons who receive the
priming dose simply fail to return to the clinic for the booster at 1
year, they may remain vulnerable. We showed that, using the VRP
platform, an effective booster immunization could be given after a
shorter interval of 6 weeks. The absence of interference by short-
lived cross-neutralizing antibodies induced by the VRP prime
may be explained by the nonpropagating nature of the VRP and
the absence of DENV antigens on the surface of the VRP particle.
Therefore, a protective 2-dose vaccine regime may be completed
in 6 weeks, reducing the period when the vaccine recipient may be
sensitized to severe disease.
Longer-term immunogenicity studies would be needed to ad-
dress the duration of the neutralizing-antibody response induced
by the vaccines beyond 18 weeks after the last immunization. We
recognize that establishing a durable immune response to all 4
serotypes may be especially important for a DENV vaccine, and it
has been an important goal for dengue vaccine developers. How-
ever, because protective efficacy was the primary endpoint of this
study, we challenged the monkeys instead of seeking long-term
immunity data.
An attempt to compare the potency and efficacy in NHPs of the
E85-VRP vaccine with those of LAV candidates currently in clin-
ical trials when they were previously tested in NHPs is described
below. The caveats in comparing these studies lie in differences in
macaque species, vaccine regimens and schedules, and assays to
determine antibody potency and protection. In our study, 16 im-
munized rhesus macaques showed 100% seroconversion after two
immunizations given 6 weeks apart, with Neut50 GMTs of 283,
446, 202, and 284 against DENV1 to -4, respectively. Our vaccine
induced complete protection against DENV3 and -4 challenges
and reduced the duration and peak titer of viremia after challenge
with DENV1 and -2. Three LAV vaccines now in clinical trials
have been previously tested in HNPs. When tetravalent yellow
fever-dengue virus chimeric vaccine, ChimeriVax/CYD-TV, was
first tested in cynomolgus macaques, a single dose (105 PFU of
each serotype) resulted in 100% seroconversion, with PRNT50
GMTs of 113, 718, 285, and 1,140 against serotypes 1 to 4, respec-
tively, on day 30 postvaccination. All monkeys had neutralization
titers at the time of challenge, 6 months later, and 22 of 24 mon-
keys were protected, as determined by lack of viremia postchal-
lenge (12). A second NHP study (90) was done with serum-free
cultured vaccine lot viruses. The study showed interferences
among the four CYD serotypes. Immunization at a single anatom-
ical site with TV CYD 5555 (the formulation used in clinical trials)
resulted in lower neutralization titers than in the previous study
and the need for more than one immunization to get neutraliza-
tion titers to serotype 2 (90). After two doses given on days 0 and
56, the PRNT50 GMTs were 80, 10, 13, and 126 against DENV1
to -4, respectively, in one experiment and 119, 10, 10, and 119
in a second experiment. Out of 8 monkeys, 100% seroconverted to
DENV1, 13% to DENV2, 50% to DENV3, and 100% to DENV4.
Protective efficacy was not reported in this study. A 1-year booster
resulted in 100% seroconversion to DENV1, -3, and -4 and 75% to
DENV2 (90). The discrepancies between the two yellow fever-
dengue virus chimeric-vaccine studies were attributed to different
culture conditions, animal origins, and assays used to assess
viremia and immunogenicity (90). Interestingly, the serotype 2
component of the vaccine was the less immunogenic in macaques
(90) and induced no significant protection in the human pilot
phase 2b study (19). When this vaccine was tested in flavivirus-
naïve humans, the seroconversion rate to three or more serotypes
after two doses was 60%, and 80 to 95% after three doses (18).
Based on these results, we feel there is not enough information yet
to evaluate the predictive value of the NHP efficacy measure-
ments. When the NIAID’s TetraVax-DV vaccine was tested in
rhesus macaques, it resulted in 100% seroconversion (defined as
4-fold or greater increase in PRNT after immunization) to all 4
serotypes after a single dose of formulation TV-2, with PRNT60
GMTs of 57, 16, 18, and 126 to DENV1 to -4, respectively, mea-
sured on day 28 postvaccination (64). Challenge with each DENV
serotype homologous strain on day 42 resulted in 100% protec-
tion from viremia against challenges with DENV1, -3, and -4, but
not -2. Protection against challenge with DENV2 was improved to
100% after a second vaccine dose administered 4 months after the
first dose. Importantly, in humans, this vaccine also confers

90% seroconversion to 3 or more serotypes after 1 dose (A.
Durbin, presented at the American Society of Tropical Medicine
and Hygiene 61st annual meeting, Atlanta, GA, 2012). The Invi-
ragen tetravalent LAV, DENVax formulation 2 (3355), when
tested in cynomolgus macaques induced seroconversion rates to
each serotype of 87.5%, 100%, 100%, and 100% after 2 doses, with
PRNT50 GMTs of 306, 554, 320, and 36 (91). Based on these earlier
reports and the results presented here, we anticipate that when
tested in humans, the TV E85-VRP vaccine will induce serotype-
specific neutralizing antibodies to all 4 DENVs after 2 doses while
inducing a qualitatively different antibody response with en-
hanced EDIII specificity compared to that of LAV vaccines.
We were unable to establish a correlation between the prechal-
lenge titer and protection from viremia. There were 2 macaques in
the DENV1 challenge group and 3 in the DENV2 challenge group
that had detectable viremia, although reduced in magnitude and
duration. Prechallenge Neut50 titers in those animals were 23, 112,
174, 170, and 50, which were not different from those in other
macaques with no detectable viremia by focus-forming assay.
These results suggest that neutralizing antibodies as measured in
this study are not the only determinants of protection in this
model.
There was a robust anamnestic response after challenge in the
VRP-vaccinated animals. The priming afforded by the vaccine
indicates that it is sufficient not only to reduce replication of the
challenge virus significantly, but also to prime a strong anamnestic
response consistent with long-lived immunity. Therefore, in an
endemic setting, vaccination combined with subsequent subclin-
ical infection could result in particularly strong and long-lasting
protective immunity.
A tetravalent E85-VRP vaccine was successful in overcoming
serotype dominance/interference when the four components of
the vaccine were mixed. One vaccine dose was sufficient to induce
a tetravalent response in 56% of nonhuman primates, and 100%
seroconversion was achieved after 2 doses. After adjustment of the
ratio of monovalent vaccines in the combination, there were no
signs of dominance or viral interference among the 4 VRP vaccine
components. First, 100% seroconversion to all 4 serotypes was
achieved after a two-dose regime with a 6-week interval, which
duplicated the rate of seroconversion for the monovalent vac-
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cines. Second, the mean Neut50 titer against DENV3 (GMT 	
202) elicited by the tetravalent formulation (Table 3) was not sig-
nificantly diminished relative to the mean titer against DENV3
elicited by the monovalent DENV3 E85-VRP (GMT 	 214)
(Table 1) given at the same dose, suggesting that the other com-
ponents of the tetravalent VRP mixture did not interfere with the
DENV3 VRP component. Although here we compared only the
monovalent versus tetravalent responses for the serotype 3 com-
ponent, in mice we compared each vaccine component indepen-
dently and in the tetravalent mixture and showed for each sero-
type that the response in the tetravalent mixture was as high as that
in the monovalent formulation (White, unpublished).
Although we did not test the tetravalent vaccine sera for neu-
tralization against multiple members of each serotype, the DENV
strains used in the neutralization assay were heterologous WHO
reference strains and therefore measured a broader neutralization
response.
The relative doses of the 4 components of the tetravalent E85-
VRP vaccine were 1:1:1:2, for serotypes 1, 2, 3, and 4, respectively.
This ratio was based on mouse studies in which E85 from DENV4
was less immunogenic than the other serotypes when equal doses
were administered as a tetravalent VRP cocktail (White, unpub-
lished). Increasing the dose of DENV4 E85-VRP 2-fold relative to
the other serotypes resulted in DENV4 neutralizing-antibody ti-
ters that were similar to those of the other 3 serotypes after the first
or second immunization. This suggests that the immune re-
sponses of individual serotypes may be modulated successfully by
changing the ratio of the VRP vaccine components.
The VRP platform combines advantages of both LAV and
killed/subunit vaccines. Similar to LAV, E85-VRP contains a rep-
licating viral RNA capable of inducing all arms of the immune
system, including a strong innate immune response. On the other
hand, as in killed and subunit vaccines, the components of the
tetravalent mixture are nonpropagating antigens; therefore, inter-
ference is minimized, resulting in a more balanced immune re-
sponse early after immunization.
The work presented here demonstrates in nonhuman primates
that a single-cycle alphavirus vector expressing a truncated soluble
form of the major DENV envelope protein is a promising second-
generation tetravalent vaccine candidate. As the E85-VRP tetrava-
lent candidate exhibits the major characteristics of a potentially
successful dengue vaccine, we suggest that further testing in clin-
ical trials is justified, including heterologous prime-boost regimes
with live attenuated vaccine candidates.
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